41.06 0.00 (0.00%)
After hours: 4:16PM EDT
|Bid||40.69 x 3000|
|Ask||41.34 x 1100|
|Day's Range||40.91 - 41.22|
|52 Week Range||36.41 - 42.49|
|Beta (3Y Monthly)||0.52|
|PE Ratio (TTM)||41.39|
|Earnings Date||Feb 1, 2017 - Feb 6, 2017|
|Forward Dividend & Yield||1.86 (4.52%)|
|1y Target Est||45.92|
The panel voted 9-6 in favour of the therapy, saying its benefits as a smoking cessation aid outweighed risks. The FDA usually follows the recommendations of its experts, but is not mandated to do so. The dose of nicotine is gradually reduced and then discontinued over a 12-week period, allowing the person to break out of the habit of smoking.
An independent expert panel to the U.S. Food and Drug Administration on Wednesday recommended approval of GlaxoSmithKline Plc's over-the-counter nicotine oral spray that aims to help smokers quit their addiction. The panel voted 9-6 in favor of the therapy, saying its benefits as a smoking cessation aid outweighed risks. The FDA usually follows the recommendations of its experts, but is not mandated to do so.
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for use in children as young as six years old who are living with severe eosinophilic asthma. Nucala is the only targeted biologic to be approved for the condition in the six to 11-year age group in the US. Dr Hal Barron, Chief Scientific Officer and President, R&D, GSK, said: “Children with severe eosinophilic asthma currently have limited treatment choices available to them.
The settlement could be valued at up to $12 billion, they said, which would make it the largest such settlement in U.S. pharmaceutical history. The following are some of the largest previous U.S. legal settlements involving the pharmaceutical industry. * Merck & Co $4.85 billion, 2007 - Three years after it pulled its widely used arthritis pain drug Vioxx from the market over safety concerns and following several product liability trials, Merck agreed to pay nearly $5 billion to settle most of the 60,000 lawsuits alleging that Vioxx caused heart attacks and strokes.
Shares of generic pharmaceutical companies rallied Friday after Perrigo announced its acquisition of GlaxoSmithKline's heartburn treatment, a medicine known as Prevacid 24-hour.
Pfizer (PFE) sales in the second half may take a hit due to business development activity, incremental currency headwinds and potentially lower sales of key drugs Prevnar and Xeljanz.
Aiming to use so-called "natural killer" cells to rev up the immune system against cancer, Nkarta Therapeutics Inc. raised $114 million from a lineup of biotech and crossover investors that hints at an IPO. The South San Francisco company, headed by biotech industry leader Paul Hastings, plans to enter clinical trials with two types of engineered natural killer cells, part of the body's innate immune system that forms a frontline defense against foreign invaders.
AstraZeneca's (AZN) second phase III study evaluating anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus meets the primary endpoint.
Emergent's (EBS) vaccine portfolio holds potential with the newly-acquired Narcan nasal spray performing well in the first half of 2019. Stiff competition is a lingering concern.
Ionis (IONS) out-licenses antisense medicines to Glaxo for treating chronic hepatitis B virus infection. Glaxo exercises its option to in-license the same. Shares fall.
Jim Cramer said on CNBC's "Mad Money Lightning Round" that he likes GlaxoSmithKline plc (NYSE: GSK ). He thinks it's terrific and the CEO is doing a great job. Cramer would sell Centurylink Inc ...
AstraZeneca's (AZN) Fasenra gets Orphan Drug status for eosinophilic oesophagitis (EoE). A phase III COPD study on Breztri Aerosphere meets primary endpoint.
Jim Cramer weighed in on a number of stocks during the Lightning Round of Mad Money Tuesday night. One name was GlaxoSmithKline plc : "I think they're terrific and they're doing a great job." Let's check out the charts of this global pharmaceutical firm. In the daily bar chart of GSK, below, we can see that prices have been making higher lows from December to the end of May to the middle of August.